DK0735863T3 - Præparat indeholdende bromocriptin med accelereret frigørelse - Google Patents

Præparat indeholdende bromocriptin med accelereret frigørelse

Info

Publication number: DK0735863T3
Authority: DK; Denmark
Prior art keywords: preparation containing; accelerated release; bromocriptine; containing bromocriptine; dosage form
Prior art date: 1993-12-22

Application number

DK95906146T

Other languages

English (en)

Inventor

Anthony N Cincotta

Manuel Cincotta Jr

Susan Louise Tigner

Christopher Eric Runice

Christopher Louis Pelloni

Original Assignee

Geneva Pharmaceuticals Inc

Ergo Science Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-22

Filing date

1994-12-22

Publication date

2002-12-16

1994-12-22 Application filed by Geneva Pharmaceuticals Inc, Ergo Science Inc filed Critical Geneva Pharmaceuticals Inc

2002-12-16 Application granted granted Critical

2002-12-16 Publication of DK0735863T3 publication Critical patent/DK0735863T3/da

Links

OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 title abstract 2
229960002802 bromocriptine Drugs 0.000 title abstract 2
239000006186 oral dosage form Substances 0.000 abstract 2
102000003946 Prolactin Human genes 0.000 abstract 1
108010057464 Prolactin Proteins 0.000 abstract 1
239000012736 aqueous medium Substances 0.000 abstract 1
238000004090 dissolution Methods 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
229940097325 prolactin Drugs 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Developing Agents For Electrophotography (AREA)
Pens And Brushes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK95906146T 1993-12-22 1994-12-22 Præparat indeholdende bromocriptin med accelereret frigørelse DK0735863T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17189793A	1993-12-22	1993-12-22
PCT/US1994/014994 WO1995017170A1 (en)	1993-12-22	1994-12-22	Accelerated release composition containing bromocriptine

Publications (1)

Publication Number	Publication Date
DK0735863T3 true DK0735863T3 (da)	2002-12-16

Family

ID=22625557

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95906146T DK0735863T3 (da)	1993-12-22	1994-12-22	Præparat indeholdende bromocriptin med accelereret frigørelse

Country Status (15)

Country	Link
US (1)	US5679685A (da)
EP (2)	EP1258245A3 (da)
JP (1)	JP3150343B2 (da)
AT (1)	ATE227566T1 (da)
AU (1)	AU1447595A (da)
CA (1)	CA2179540C (da)
DE (1)	DE69431729T2 (da)
DK (1)	DK0735863T3 (da)
ES (1)	ES2186711T3 (da)
IL (1)	IL112106A0 (da)
MX (1)	MX9500243A (da)
PT (1)	PT735863E (da)
TW (1)	TW389696B (da)
WO (1)	WO1995017170A1 (da)
ZA (1)	ZA9410263B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030026835A1 (en) *	1999-02-15	2003-02-06	Sumitomo Pharmaceuticals Company Limited	Tablets disintegrating rapidly in the oral cavity
US20070243240A9 (en) *	2000-08-24	2007-10-18	Fred Windt-Hanke	Transdermal therapeutic system
DE10053397A1 (de) *	2000-10-20	2002-05-02	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) *	2000-08-24	2005-07-28	Neurobiotec Gmbh	Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) *	2000-12-16	2002-07-04	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
FR2834889B1 (fr) *	2002-01-18	2004-04-02	Roquette Freres	Forme pharmaceutique solide orodispersible
US20030228370A1 (en) *	2002-06-11	2003-12-11	Michel Serpelloni	Orodispersible solid pharmaceutical form
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
US20040220190A1 (en) *	2002-07-29	2004-11-04	Cincotta Anthony H.	Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en)	2002-07-29	2017-05-23	Veroscience, Llc	Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en)	2002-08-09	2014-09-02	Veroscience, Llc	Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
ATE361742T1 (de) *	2003-05-19	2007-06-15	Euro Celtique Sa	Verwendung von seifen wie magnesium stearate zur beschleunigung der freisetzung von wirkstoffen
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20100035886A1 (en)	2007-06-21	2010-02-11	Veroscience, Llc	Parenteral formulations of dopamine agonists
US8741918B2 (en) *	2007-06-21	2014-06-03	Veroscience Llc	Parenteral formulations of dopamine agonists
EP3524248A1 (en)	2007-06-21	2019-08-14	VeroScience LLC	Method of treating metabolic disorders and depression with dopamine receptor agonists
US9352025B2 (en)	2009-06-05	2016-05-31	Veroscience Llc	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
CN102639118B (zh)	2009-07-22	2015-07-29	格吕伦塔尔有限公司	氧化稳定的抗干扰剂型
KR101738369B1 (ko)	2009-07-22	2017-05-22	그뤼넨탈 게엠베하	핫 멜트 압출된 제어 방출 투여형
BR112013005194A2 (pt)	2010-09-02	2016-05-03	Gruenenthal Gmbh	forma de dosagem resistente à violação compreendendo sal inorgânico
BR112014001091A2 (pt)	2011-07-29	2017-02-14	Gruenenthal Gmbh	comprimido resistente à adulteração que fornece liberação imediata do fármaco
EA201400172A1 (ru)	2011-07-29	2014-06-30	Грюненталь Гмбх	Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
EP2838512B1 (en)	2012-04-18	2018-08-22	Grünenthal GmbH	Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US8431155B1 (en)	2012-04-30	2013-04-30	Veroscience Llc	Bromocriptine formulations
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN113842362A (zh)	2012-11-14	2021-12-28	格雷斯公司	含有生物活性材料与无序无机氧化物的组合物
EP3003279A1 (en)	2013-05-29	2016-04-13	Grünenthal GmbH	Tamper-resistant dosage form containing one or more particles
EP3073994A1 (en)	2013-11-26	2016-10-05	Grünenthal GmbH	Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015173195A1 (en)	2014-05-12	2015-11-19	Grünenthal GmbH	Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru)	2014-05-26	2017-05-31	Грюненталь Гмбх	Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
WO2016170097A1 (en)	2015-04-24	2016-10-27	Grünenthal GmbH	Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja)	2015-09-10	2018-09-13	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
DK3445362T3 (da)	2016-04-20	2021-10-11	Veroscience Llc	Sammensætning og fremgangsmåde til behandling af stofskiftesygdomme
WO2019079623A1 (en)	2017-10-18	2019-04-25	Veroscience Llc	ENHANCED BROMOCRIPTINE FORMULATIONS
US11607455B2 (en)	2019-09-23	2023-03-21	Veroscience Llc	Method for inducing tumor regression
CN116350631A (zh) *	2023-05-12	2023-06-30	上海市肺科医院（上海市职业病防治院）	溴隐亭在制备治疗肺动脉高压药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3074847A (en) *	1960-04-27	1963-01-22	Frank L Bigsby	Appetite control composition
CH507249A (de) *	1968-05-31	1971-05-15	Sandoz Ag	Verfahren zur Herstellung von 2-Brom-a-ergokryptin
CA990287A (en) *	1972-09-26	1976-06-01	Sandoz Patents Limited	13-bromo-lysergic acid compounds
US3849562A (en) *	1973-03-15	1974-11-19	Sandoz Ltd	Method of treating nephrosis
US3922347A (en) *	1974-12-19	1975-11-25	Lilly Co Eli	Method of inhibiting prolactin secretion with 8-acylaminoergolenes
US4054660A (en) *	1975-04-14	1977-10-18	Eli Lilly And Company	Method of inhibiting prolactin
US4151283A (en) *	1977-02-17	1979-04-24	Societa' Farmaceutici Italia S.P.A.	6-Methyl-and 1,6-dimethyl-8β-carbobenzyloxy-aminomethyl-10α-ergoline as inhibitors of prolactin secretion
YU216177A (en) *	1977-09-09	1984-02-29	Rudolf Rucman	Process for preparing 2-bromo ergosine
IT1157365B (it) *	1977-10-24	1987-02-11	Sandoz Ag	Medicamenti per trattare l'obesita' o ridurre il peso del corpo
BE890369A (fr) *	1980-09-18	1982-03-16	Sandoz Sa	Nouveaux medicaments a base d'inhibiteurs de la secretion de la prolactine pour le traitement de l'arteriosclerose
DE3216870A1 (de) *	1982-05-03	1983-11-03	Schering AG, 1000 Berlin und 4709 Bergkamen	Pharmazeutische zubereitungen mit zytostatischer wirkung
GB2154874B (en) *	1984-02-29	1987-11-04	Sandoz Ltd	Bromoscriptine compositions
US4935429A (en) *	1985-10-25	1990-06-19	Dackis Charles A	Method of treating psychostimulant addiction
US4749709A (en) *	1986-03-07	1988-06-07	Louisiana State University And Agricultural And Mechanical College	Method of inhibiting body fat stores
US4783469A (en) *	1986-03-07	1988-11-08	Meier Albert H	Method of inhibiting body fat stores
US4659715A (en) *	1986-03-07	1987-04-21	Louisiana State University And Agricultural And Mechanical College	Method of inhibiting body fat stores
DE3722383A1 (de) *	1986-07-14	1988-01-28	Sandoz Ag	Neue verwendung von bromocriptin
DE3868866D1 (de) *	1987-11-20	1992-04-09	Erba Carlo Spa	Ergolinderivate mit antiparkinsonwirkung.
US5073555A (en) *	1988-04-04	1991-12-17	George D. McAdory	Medicaments intended for combined use in the improvement of lymphocyte function to lower cholesterol levels
US5344832A (en) *	1990-01-10	1994-09-06	The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College	Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5006526A (en) *	1988-10-17	1991-04-09	Louisiana State University	Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
US5073374A (en) *	1988-11-30	1991-12-17	Schering Corporation	Fast dissolving buccal tablet
IT1235053B (it) *	1989-04-07	1992-06-17	Poli Ind Chimica Spa	Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti.
DK469989D0 (da) *	1989-09-22	1989-09-22	Bukh Meditec	Farmaceutisk praeparat
US5229131A (en) *	1990-02-05	1993-07-20	University Of Michigan	Pulsatile drug delivery system
US5221536A (en) *	1990-05-07	1993-06-22	Alza Corporation	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) *	1990-05-07	1993-03-02	Alza Corporation	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5128145A (en) *	1990-06-13	1992-07-07	Alza Corporation	Dosage form for Parkinson's disease, spasticity and muscle spasms
WO1993012793A1 (en) *	1991-12-23	1993-07-08	The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	A therapeutic process for the treatment of the pathologies of type ii diabetes
FR2690340B1 (fr) *	1992-04-24	1995-02-24	Scr Newmed	Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant.

1994
- 1994-12-21 IL IL11210694A patent/IL112106A0/xx not_active IP Right Cessation
- 1994-12-22 EP EP02018888A patent/EP1258245A3/en not_active Withdrawn
- 1994-12-22 DK DK95906146T patent/DK0735863T3/da active
- 1994-12-22 ES ES95906146T patent/ES2186711T3/es not_active Expired - Lifetime
- 1994-12-22 WO PCT/US1994/014994 patent/WO1995017170A1/en not_active Ceased
- 1994-12-22 ZA ZA9410263A patent/ZA9410263B/xx unknown
- 1994-12-22 AT AT95906146T patent/ATE227566T1/de active
- 1994-12-22 CA CA002179540A patent/CA2179540C/en not_active Expired - Fee Related
- 1994-12-22 AU AU14475/95A patent/AU1447595A/en not_active Abandoned
- 1994-12-22 JP JP51764495A patent/JP3150343B2/ja not_active Expired - Fee Related
- 1994-12-22 DE DE69431729T patent/DE69431729T2/de not_active Expired - Lifetime
- 1994-12-22 PT PT95906146T patent/PT735863E/pt unknown
- 1994-12-22 EP EP95906146A patent/EP0735863B1/en not_active Expired - Lifetime
1995
- 1995-01-02 MX MX9500243A patent/MX9500243A/es unknown
- 1995-03-04 TW TW084102083A patent/TW389696B/zh active
- 1995-06-02 US US08/459,021 patent/US5679685A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0735863A1 (en)	1996-10-09
US5679685A (en)	1997-10-21
IL112106A0 (en)	1995-03-15
DE69431729D1 (de)	2002-12-19
CA2179540C (en)	2002-05-14
MX9500243A (es)	1997-02-28
CA2179540A1 (en)	1995-06-29
EP0735863B1 (en)	2002-11-13
EP1258245A2 (en)	2002-11-20
EP0735863A4 (en)	1997-08-20
JPH09510955A (ja)	1997-11-04
TW389696B (en)	2000-05-11
WO1995017170A1 (en)	1995-06-29
EP1258245A3 (en)	2003-01-02
AU1447595A (en)	1995-07-10
PT735863E (pt)	2003-03-31
ES2186711T3 (es)	2003-05-16
DE69431729T2 (de)	2003-07-17
JP3150343B2 (ja)	2001-03-26
ATE227566T1 (de)	2002-11-15
ZA9410263B (en)	1995-08-29

Publication	Publication Date	Title
DK0735863T3 (da)	2002-12-16	Præparat indeholdende bromocriptin med accelereret frigørelse
EP1736147A3 (en)	2007-10-17	Non-chlorofluorocarbon aerosol formulations
AU6060896A (en)	1996-10-03	Oral 1alpha-hydroxyprevitamin D
CA2111002A1 (en)	1992-12-23	Non-Chlorofluorocarbon Aerosol Formulations
DK568687A (da)	1988-05-01	Hydromorphonpraeparat med reguleret afgivelse
BG104620A (en)	2001-04-30	Oral pharmaceutical extended release dosage form
GEP20043269B (en)	2004-06-25	Purine Derivatives, Method for Their Production and Composition Containing the Same
IL100502A0 (en)	1992-09-06	Pharmaceutical compositions containing 1,3-oxathiolane nucleoside analogues
HU9302493D0 (en)	1993-11-29	Application of 5-fluorine-2'-desoxi-3'-thia-cytidine for treatment of hepatitis b
MY118371A (en)	2004-10-30	Tetrahydrolipstatin containing compositions
AU2553992A (en)	1993-04-27	Bone-growth-stimulating composition
DE69105040D1 (de)	1994-12-15	Arzneimittel gegen Impotenz.
ZA898667B (en)	1990-10-31	Use of acetyl l-carnitine in the therapeutic treatment of cataract and pharmaceutical compositions useful in such treatment
NO962752L (no)	1996-08-29	Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
ES2026304A6 (es)	1992-04-16	Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
GR3025518T3 (en)	1998-02-27	Use of the N-n-butyl derivative of desoxynojirimycin in the manufacture of a medicament inhibiting HIV-Virus
EP0207882A3 (de)	1990-01-31	Verwendung von Tergurid zur Herstellung eines Arzneimittels zur Behandlung geriatrischer Beschwerden
CY2337B1 (en)	2004-02-06	Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 invection.
DK0457336T3 (da)	1995-08-07	Ny anvendelse af 4-carbamoyl-1-beta-D-ribofuranosylimidazolium-5-olat
ZA968315B (en)	1997-04-04	Administration by inhalation of 2-amino-6n-propyl-amino-4,5,,7-tetrahydrobenzothiazole particularly the (-)-enan-tiomer thereof and the pharmacologically acceptable acid addition salts thereof
ITLE920004V0 (it)	1992-06-17	Mutandina - pannolino in cotone 100% utile per la prevenzione e cura della displasia dell'anca per i neonati